Pharmacy Times

JUNE 16, 2025

The findings emphasize nemolizumab’s swift response in treating atopic dermatitis symptoms, along with its long-term effectiveness in prurigo nodularis, as demonstrated in the OLYMPIA open-label extension trial (NCT04204616). Mayo Clinic. News release. June 6, 2025. Accessed June 16, 2025. Atopic Dermatitis. News release.

Compounding Pharmacies 65

Compounding Pharmacies FDA Immunization Mayo Clinic 65

Pharmacy Times

JUNE 23, 2025

This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.

FDA 65

FDA Compounding Pharmacies Dosage Hospitals 65

Pharmacy Times

JULY 7, 2025

1 DOORwaY 90 Study Results The approval was supported by data from the prospective, multicenter, open-label, single-arm DOORwaY 90 study that evaluated the safety and efficacy of Y-90 resin microspheres in individuals with unresectable HCC. Mayo Clinic. News release. July 7, 2025. Accessed July 7, 2025. Liver cancer.

FDA 50

FDA Compounding Pharmacies Immunization Mayo Clinic 50

Pharmacy Times

JUNE 9, 2025

These treatments are already in widespread use across health systems, from Mayo Clinic’s 9 active and 5 pending to University of California (UC) San Diego Health’s 12 active and 5 under review. At Children’s Hospital of Philadelphia (CHOP), eligible patients can access 12 advanced therapeutics and 8 more in the pipeline.

Compounding Pharmacies 56

Compounding Pharmacies FDA Hospitals Immunization 56

Pharmacy Times

JULY 9, 2025

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). Mayo Clinic. million individuals in the United States aged 65 and older.

Labelling 65

Labelling FDA Compounding Pharmacies Independent Pharmacies 65

Pharmacy Times

JUNE 15, 2025

In the randomized, open-label, multicenter phase 3 NATALEE clinical trial (NCT05306340), ribociclib (Kisqali; Novartis) plus endocrine therapy, a nonsteroidal aromatase inhibitor (NSAI), significantly improved invasive disease-free survival among individuals with HR-positive (HR+) and HER2-negative (HER2-) early breast cancer.

Mayo Clinic 106

Mayo Clinic Compounding Pharmacies Immunization Specialty Pharmacies 106

Pharmacy Times

JULY 14, 2025

SHOW MORE The expanded instructions for use labeling expand on the Farawave and Farawave Nav Pulsed Field Ablation (PFA) catheters. Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System. Mayo Clinic. News release. July 7, 2025. Accessed July 7, 2025. Atrial fibrillation.

Labelling 65

Labelling FDA Compounding Pharmacies Hospitals 65